GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alseres Pharmaceuticals Inc (OTCPK:ALSE) » Definitions » ROC %

Alseres Pharmaceuticals (Alseres Pharmaceuticals) ROC % : -623.10% (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is Alseres Pharmaceuticals ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Alseres Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Jun. 2014 was -623.10%.

As of today (2024-05-22), Alseres Pharmaceuticals's WACC % is 0.00%. Alseres Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Alseres Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Alseres Pharmaceuticals ROC % Historical Data

The historical data trend for Alseres Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alseres Pharmaceuticals ROC % Chart

Alseres Pharmaceuticals Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -45.58 -8.93 -5.07 -7.06 -16.72

Alseres Pharmaceuticals Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.43 -17.65 11.48 -906.85 -623.10

Alseres Pharmaceuticals ROC % Calculation

Alseres Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2013 is calculated as:

ROC % (A: Dec. 2013 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2012 ) + Invested Capital (A: Dec. 2013 ))/ count )
=-0.565 * ( 1 - 0% )/( (6.61 + 0.147)/ 2 )
=-0.565/3.3785
=-16.72 %

where

Alseres Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2014 is calculated as:

ROC % (Q: Jun. 2014 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2014 ) + Invested Capital (Q: Jun. 2014 ))/ count )
=-1.268 * ( 1 - 0% )/( (0.145 + 0.262)/ 2 )
=-1.268/0.2035
=-623.10 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2014) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alseres Pharmaceuticals  (OTCPK:ALSE) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Alseres Pharmaceuticals's WACC % is 0.00%. Alseres Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Alseres Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Alseres Pharmaceuticals ROC % Related Terms

Thank you for viewing the detailed overview of Alseres Pharmaceuticals's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alseres Pharmaceuticals (Alseres Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
275 Grove Street, Suite 2-400, Auburndale, MA, USA, 02466
Alseres Pharmaceuticals Inc is a US-based biotechnology company. It is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system. The company's lead product candidate is Altropane, a proprietary molecular imaging agent which is used to diagnose Parkinson's disease and dementia. Further, it is focused on entering into partnerships to ensure development and commercialization of its product. Geographically the firm carries out its business through the region of United States.
Executives
Mark Jerome Pykett officer: President and COO 223A MAIN ST, BOXFORD MA 021921
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Peter G Savas director, officer: Chief Executive Officer 110 HARTWELL AVENUE, LEXINGTON MA 02173
John T Preston director C/O MOLTEN METAL TECHNOLOTY INC, 400-2 TOTTEN POND ROAD, WALTHAM MA 02154
Rice Kenneth L Jr officer: Exec VP of Fin & Admin & CFO C/O 85 MAIN STREET, HOPKINTON MA 01748
Joseph P Hernon officer: Chief Financial Officer 1607 PONCE DE LEON AVENUE, SUITE 407, SAN JUAN PR 00909
Stephen M Peck director P O BOX 554, 3600 S LAKE DRIVE, ST FRANCIS WI, MILWAUKEE WI 53201-0554

Alseres Pharmaceuticals (Alseres Pharmaceuticals) Headlines